HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Requiring Infant Formula, Medical Food Shortage Updates Included In US FDA Budget Request

Executive Summary

FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.

You may also be interested in...



Supply Chain: A Science Food, Drug And Device Industries And US FDA Should Study – Califf

Topping Califf’s list of getting ready for future is “a vast need at the FDA for integrative data science." In a review he conducted of improvements agency centers are targeting, each listed supply chain information as top concern.

House Appropriation Leaders Propose Emergency Funding For FDA's Infant Formula Programs

Democrats introduce bill two days before Agriculture, Rural Development, FDA and Related Agencies subcommittee will question FDA Commissioner Robert Califf about agency’s oversight of formula industry during a hearing on FY2023 budget.

US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall

House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel